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Normocalcemic Hyperparathyroidism: Study of its 
Prevalence and Natural History
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Jennifer S. Walsh,1 and Richard Eastell1
1Department of Oncology and Metabolism, University of Shefield, S10 2TN, Shefield, UK; 2School of 
Health and Related Research, University of Shefield, S1 4DA, Shefield, UK; and 3Shefield Teaching 
Hospitals National Health Service Foundation Trust, S5 7AU, Shefield, UK
ORCiD numbers: 0000-0003-2204-2095 (M. Schini).
Context: Normocalcemic hyperparathyroidism (NPHPT) is characterized by persistently normal 
calcium levels and elevated parathyroid hormone (PTH) values, after excluding other causes of 
secondary hyperparathyroidism. The prevalence of the disease varies greatly and the data on 
the natural history of this disease are sparse and inconclusive.
Objectives: The objectives of this study are to describe the prevalence of NPHPT and its natural 
history in a referral population and to compare the variability of serum calcium with a group of 
patients with primary hyperparathyroidism (PHPT).
Design: A retrospective study was conducted over 5 years.
Setting: The setting for this study was a metabolic bone referral center.
Patients: A total of 6280 patients were referred for a bone mineral density measurement (BMD).
Main Outcome Measures: The prevalence and natural history of NPHPT and variability of 
calcium were the main outcome measures.
Results: We identiied NPHPT patients using data from the day of the BMD measurement. 
We excluded patients with low estimated glomerular iltration rate (eGFR) or vitamin D, or 
with no measurements available. Based on the evaluation of their medical iles, we identiied 
11 patients with NPHPT (prevalence 0.18%). Only 4 patients had consistent normocalcemia 
throughout their follow-up, with only 2 also having consistently high PTH. None had 
consistently normal eGFR or vitamin D.
Intermittent hypercalcemia was present in 7 of the 11 NPHPT patients. The mean adjusted 
calcium was found to be signiicantly lower in the NPHPT group compared with the PHPT group 
but higher than the control group. PTH was similar for NPHPT and PHPT. These 2 groups had 
similar variability in serum calcium.
Conclusions: NPHPT patients often have episodes of hypercalcemia. We believe that NPHPT is a 
mild form of PHPT. (J Clin Endocrinol Metab 105: 1–13, 2020)
Key Words:  normocalcemic hyperparathyroidism, prevalence, natural history, epidemiology, 
primary hyperparathyroidism
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N
ormocalcemic hyperparathyroidism (NPHPT) 
is a disorder of calcium metabolism that, des-
pite being mentioned in the literature for several years, 
was oficially deined only in 2009, during the Third 
International Workshop on Asymptomatic Primary 
Hyperparathyroidism (PHPT) (1). According to the 
latest guidelines, persistently normal calcium levels 
(total and ionized) and consistently elevated parathy-
roid hormone (PTH) values characterize NPHPT. The 
panel suggested that normal calcium has to be con-
irmed on several occasions and that an elevated PTH 
measurement should be conirmed on at least 2 con-
secutive measurements. Other causes of secondary 
hyperparathyroidism have to be excluded; these include 
medications known to affect PTH levels (diuretics, 
lithium, denosumab, bisphosphonates, anticonvulsants, 
and phosphorus), low vitamin D, chronic kidney disease 
(estimated glomerular iltration rate [eGFR] < 60  mL/
min/1.73  m2), renal calcium loss (hypercalciuria) and 
diseases of the gastrointestinal tract known to affect 
calcium absorption (celiac disease, inlammatory bowel 
disease, and bariatric surgery) (1-3).
NPHPT is usually encountered during the labora-
tory evaluation of osteoporosis and has been associated 
with consequences known to affect patients with PHPT 
(accelerated bone loss, kidney stones, higher levels of 
blood pressure, and higher preexisting glucose intoler-
ance). However, there is no clear evidence for any such 
associations (4, 5).
The prevalence of NPHPT in the literature varies 
considerably, and it is reported to be between 0.1% and 
8.9% (5). The reasons for this variation are that dif-
ferent deinitions and methodologies were used in the 
reported studies; not all causes of secondary hyperpara-
thyroidism were excluded, and some studies did not test 
the persistence of high PTH and normal calcium before 
evaluating the prevalence; thus the results were prob-
ably overestimated.
The data on the natural history of this disease are also 
sparse and inconclusive. Some studies show progression 
to hypercalcemia, but others do not. The way that many 
studies identify NPHPT patients is by testing calcium and 
PTH at baseline, and retesting after some time to check 
whether they progressed to hypercalcemia. The vari-
ability of calcium in NPHPT during the follow-up period 
has been poorly described. One study has described the 
variability as similar to the normal population, whereas 
patients with PHPT have been described to have more 
considerable variability in calcium levels (6). However, 
there are not enough data to draw any conclusions.
According to the proceedings of the Fourth 
International Workshop on Asymptomatic Primary 
Hyperparathyroidism, NPHPT remains incompletely 
described, especially regarding its epidemiology, nat-
ural history, and management (4). The criteria are not 
clear concerning how many measurements are needed 
to establish a diagnosis, which makes the matter com-
plicated for the clinician and confusing for the patient. 
This study aims to identify the prevalence of NPHPT 
and study the natural history of this disorder in more 
detail. It also aimed to compare the variability of cal-
cium and PTH between PHPT and NPHPT patients.
Methods
Study population
This work was performed at the Metabolic Bone Centre 
(MBC) at Shefield Teaching Hospitals National Health 
Service Foundation Trust (STH NHS FT) in the United 
Kingdom. Data from patients referred for a bone mineral 
density (BMD) measurement between January 14, 2013 and 
July 27, 2017 were retrospectively evaluated. Patients were in-
cluded in the database if they had a laboratory evaluation, 
including calcium and PTH, performed within 28 days of their 
scan. In general, this department evaluated approximately 650 
patients per month at the time of the study and a laboratory 
workup for secondary osteoporosis was performed in pa-
tients having any of the following indings: low BMD for age 
(Z score < –2.0), vertebral fracture, or unexplained bone loss 
since the previous scan. The day of the laboratory investiga-
tions was deined to be the index day. More results of calcium 
and PTH before and after the index day were retrieved from 
hospital records and were used to study the natural history of 
the disease. Only data collected after January 14, 2013 were 
evaluated because at that point, the laboratory changed the 
assay for serum calcium, and this would probably affect the 
accuracy of the results. The end of the follow-up period was 
July 31, 2018.
The analysis was considered a case note review project by 
Shefield Teaching Hospitals and did not require a special eth-
ical approval (project number STH20617).
Biochemical measurements
Blood was drawn at any point of the day, so patients were 
not fasting. All the samples were analyzed in the Chemical 
Pathology Laboratory, STH NHS FT. Intact PTH (second 
generation) was measured using an immunoassay method 
by the Roche Cobas 8000 e602 (Roche Diagnostics GmbH). 
The interassay coeficient of variation (CV) measured in the 
laboratory is 2.2% to 3.2% at 34  ng/L, 1.6% to 1.7% at 
94 ng/L, and 1.4% to 1.8% at 839 ng/L, and the reported ref-
erence interval is 15 to 65 ng/L (1.6-6.9 pmol/L).
Serum calcium was measured using a Roche/Hitachi Cobas 
8000 e702 automated clinical chemistry analyzer (Roche). 
This method uses 5-nitro-5’-methyl-BAPTA reagent. The 
interassay CV as measured in the laboratory is 1.1% to 1.5% 
at 1.52 mmol/L and 0.6% to 1.1% at 3.07 mmol/L. Albumin 
measurement was performed using a Roche/Hitachi Cobas 
8000 e702 analyzer (Roche). The interassay CV as measured 
by the laboratory is 1.5% to 2.4% at 33.9 g/L and 1.0% to 
1.7% at 59.7  g/L. The albumin-adjusted calcium was used 
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for this study and was calculated using the following equa-
tion based on data from the local laboratory. The method by 
which the laboratory established its equation was based on a 
protocol published by Barth et al (7).
Adjusted Ca = Total Ca+ [0.0172 (43− Albumin)]
The reference interval for adjusted calcium is 2.20 to 
2.60 nmol/L (8.8-10.4 mg/dL).
25-hydroxyvitamin D (25(OH)D) was measured using 
the IDS-iSYS automated immunoassays (Immunodiagnostic 
Systems) until May 2013. The interassay CV reported by the 
manufacturer was 10.4% at 64.5  nmol/L. The assay then 
changed to competitive binding protein and was performed by 
Roche modular analytics Cobas E170 (Roche). The laboratory 
interassay CV for this assay is 6.5% to 9.9% at 48.2 nmol/L 
and 4.5% to 6.3% at 92.3  nmol/L. The Shefield Teaching 
Hospitals laboratory was participating in the UK Vitamin D 
External Quality Assessment Scheme at the time of this study.
Creatinine was measured using a Roche/Hitachi Cobas 
c8000 e702 analyzer (Roche). The interassay CV for this 
assay was 2.7% to 6.1% at 55.7 μmol/L and 2.3% to 4.0% 
at 458 μmol/L. The equation used to calculate eGFR was the 
Modiication of Diet in Renal Disease Study equation:
eGFR
Å
mL
min× 1.73 m2
ã
=175× (Serum creatine)
−1154
× age−0.203 × [0.742 if female]
× [1.212 if black]
This equation changed in August 2015; the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation has 
been in use since then.
eGFR
Å
mL
min× 1.73 m2
ã
=141×min
Å
Scr
k
, 1
ã
α
×max
Å
Scr
k
, 1
ã
−1.209
× 0.993
age
× 1.018 [if female] × 1.159 [if black]
Scr is serum creatinine in mg/dL, κ is 0.7 for female and 0.9 
for male patients, α is –0.329 for female and –0.411 for male 
patients, min indicates the minimum of Scr/κ or 1, and max 
indicates the maximum of Scr/κ or 1 (8).
Alkaline phosphatase was measured using a Roche/Hitachi 
Cobas c8000 e702 analyzer. The interassay CV for this assay 
was 2.4% at 92.8 IU/L and 1.7% at 224 IU/L. The same ana-
lyzer was used for the measurement of serum phosphate and 
the interassay CV was 1.4% at 1.23  mmol/L and 1.2% at 
2.04 mmol/L.
BMD was performed using dual-energy X-ray absorpti-
ometry (DXA) of the lumbar spine and the proximal femur 
in posteroanterior projection. At the time of the study, there 
were 3 Hologic DXA scanners within the center. The least sig-
niicant change (LSC) used in the MBC was 4.5% both for 
the spine and the hip. There were 3  scanning rooms in the 
department and each room has a different scanner. Room A: 
Hologic Discovery A  has been in use since 2010. Room B: 
Hologic QDR4500A was in use from 2011 until September 
11, 2013. The scanner was then decommissioned and re-
placed by a Hologic Discovery SL. Room C: Hologic Delphi 
C was in use until November 3, 2014. The scanner was then 
decommissioned and replaced by a Hologic Horizon A. The 
different DXA scanners were cross-calibrated at installation.
Statistical Analysis
Because calcium and PTH are not independent variables, 
a bivariate statistical approach was used to deine the 
different categories of patients. Mahalanobis distance 
is a multidimensional generalization of the concept of 
measuring the number of SDs away an observation is 
from the mean of a distribution. It is a classical method 
of deining outliers in a multivariate point cloud and 
is deined for each point xi, by the following equation, 
where MDi: Mahalanobis distance, μ: arithmetic mean 
of the data set, and S: sample covariance matrix.
MD
2
i = (xi − µ)
T
S
−1(xi − µ)
The distance MDi gives the distance of point xi from the 
center of the cluster of points, taking into account the 
shape of the cluster. Observations are considered out-
liers if MD2 > Χ 22;0.975 = 7.378 (97.5th percentile of chi-
squared distribution with 2 degrees of freedom) (9, 10). 
The correlation analysis of adjusted calcium and PTH 
was performed based on a log10 transformation of the 
2 variables. A similar approach has been used in the past 
to evaluate the prevalence of NPHPT in a different group 
of patients. According to this method, participants were 
identiied as “normal” if they were inside the ellipse and 
“abnormal” if they were outside (Fig. 1). To get the dif-
ferent categories described below, researchers used the 
reference interval for adjusted calcium. However, they 
used the geometric mean of the reference interval for 
PTH (11). We have adjusted this method and brought it 
closer to everyday clinical practice by using the clinical 
reference intervals both for adjusted calcium and PTH. 
Doing so, patients were divided into 10 categories as 
described as follows. “High” or “low” refer to values 
of either adjusted calcium or PTH being greater than or 
less than the reference interval, respectively.
To compare the variability of different analytes in 
the 3 groups, the overall mean and the pooled within-
subject SD of each analyte was calculated. The ANOVA 
method was used to calculate the within-subject vari-
ance because this method addresses the case of parti-
cipants having different numbers of observations. To 
follow this method, we irst checked the assumption that 
the SD was unrelated to the magnitude of the measure-
ment. This was performed graphically, by plotting the 
individuals’ SDs against their means and analytically by 
calculating a rank correlation coeficient (12).
To compare characteristics between the groups at 
baseline, one-way ANOVA and Kruskal-Wallis were 
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used to compare the quantitative data. The results are 
presented as mean and SD when ANOVA was used 
for the analysis, as geometric mean and 95% CI, when 
log transformation was performed before analysis 
with ANOVA, or as median and interquartile range 
if nonparametric tests were used for the analysis. The 
Mann-Whitney test was used to compare the 24-hour 
urine calcium between the NPHPT and PHPT groups. 
For the comparison of the overall measurements of PTH 
and adjusted calcium resulting from follow-up, we used 
a mixed linear model. Individual variability was mod-
eled using a random effect and the difference between 
groups was estimated using a ixed effect.
The statistical analyses have been performed 
using R studio statistical software, version 1.1.442 
(RStudio, Inc).
Deinitions of different groups
As mentioned in the “Statistics” section, pa-
tients were divided into 10 categories based on their 
laboratory intervals for adjusted calcium and PTH. 
The cutoff for normal vitamin  D was 50  nmol/L ac-
cording to the Royal Osteoporosis Society guidelines 
(13). The categories were deined as follows. Normal: 
anyone inside the ellipse; the rest of the groups de-
scribed were outside the ellipse. Hyperparathyroid 
hypercalcemia (HH) included patients with PHPT, and 
familial hypocalciuric hypercalcemia (FHH) and was 
deined as anyone outside the ellipse having high ad-
justed calcium and high PTH. Hypoparathyroidism: 
low adjusted calcium and low PTH. Secondary hyper-
parathyroidism: a) low adjusted calcium and high PTH 
or, b) normal adjusted calcium and high PTH with 
25(OH)D less than 50 nmol/L or eGFR less than 60 mL/
min/1.73  m2. Non-PTH hypercalcemia: high adjusted 
calcium and low PTH. NPHPT: normal adjusted cal-
cium and high PTH, given that 25(OH)D ≥ 50 nmol/L 
and eGFR ≥ 60 ml/min/1.73 m2. Normocalcemic hypo-
parathyroidism: normal adjusted calcium and low 
PTH. Normoparathyroid hypercalcemia: high adjusted 
Figure 1. Data results from adjusted calcium and parathyroid hormone (PTH). The ellipse was formed using a statistical method (Mahalanobis 
distance) to identify “normal” individuals (black dots) and “abnormal” ones (red dots). The reference interval both of adjusted calcium and PTH 
(horizontal and vertical dashed lines, respectively), were used to identify patient categories. The deinitions used are described in the “Methods” 
section. The white area includes patients with normal adjusted calcium and high PTH (n = 265); these were either potentially NPHPT patients 
(given that 25[OH]D ≥ 50 nmol/L and estimated glomerular iltration rate [eGFR] ≥ 60 mL/min/1.73 m2) or secondary hyperparathyroidism patients 
(given that 25[OH]D < 50 nmol/L and/or eGFR < 60 mL/min/1.73 m2). NPHPT, normocalcemic hyperparathyroidism; NHYPO, normocalcemic 
hypoparathyroidism.
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calcium and normal PTH. Normoparathyroid hypo-
calcemia: low adjusted calcium and normal PTH. 
Unidentiied: normal adjusted calcium and normal PTH 
but being outside the ellipse. The groups of interest for 
this study were the normal population and the patients 
with HH and NPHPT. To characterize these groups fur-
ther, the following procedures were followed.
For the NPHPT patients identiied from the index 
date, a careful evaluation of their medical records and 
other laboratory investigations were performed to check 
for exclusion criteria according to the guidelines (see the 
introductory section). Renal calcium loss was deined as 
having 24-hour urine calcium greater than or equal to 
6.25 mmol/24 h for women or 7.5 mmol/24 h for men 
and/or 0.1 mmol/kg/24 h or greater (14). Moreover, and 
to be in line with the international guidelines on per-
sistence, only patients with persistently normal adjusted 
calcium and elevated PTH on 2 consecutive occasions 
were included.
For the HH patients, only the patients with vitamin 
D greater than or equal to 50 nmol/L and eGFR greater 
than or equal to 60 mL/min/1.73m2 on the index date 
were chosen to be used for the variability analysis. 
An evaluation of their medical iles excluded patients 
with other diseases such as renal transplant. Results 
after parathyroid surgery were excluded. Once again, 
only patients with consistently high calcium and PTH 
on at least 2 consecutive occasions were included. To 
include only patients with PHPT in this group, one or 
more of the following criteria were used: 24-hour urine 
calcium greater than 2.5  mmol/24  h or fractional ex-
cretion greater than 0.02; or surgically proven PHPT 
(correction of high calcium after parathyroid surgery). 
This was performed to exclude FHH. At this point, all 
remaining patients in this group were deined as PHPT.
For the control population, a random sample of 300 
individuals from inside the ellipse having normal eGFR 
and being vitamin D replete (as deined previously) on 
the index date was chosen.
Results
In total, 6293 patients attended the Metabolic Bone 
Centre and were assessed for secondary osteoporosis 
from January 2013 to July 2017. All these patients 
had a BMD measurement and a laboratory evalu-
ation. Thirteen patients did not have PTH available 
on the index day and were excluded. The total number 
of patients analyzed was 6280; their mean age was 
66 years (range, 16-100 years), and 4527 (72%) were 
female. After applying the Mahalanobis distance, the el-
lipse seen in Fig. 1 was drawn. In total, 5574 patients 
were inside the ellipse and were considered “normal,” 
whereas the rest were outliers and were divided into 
disease categories using the laboratory reference interval 
for calcium and PTH (Table 1).
In total, 28 patients initially fulilled the inclusion cri-
teria for NPHPT (normal calcium, high PTH, both on 
at least 2 occasions, normal eGFR and vitamin D replete 
on index day). A careful evaluation of their medical rec-
ords and their medical history excluded 17 patients 
(Table 2). The natural history was then studied, using 
calcium measurements available from January 2013 to 
the end of July 2018. Two patients were excluded be-
cause of PTH inconsistency (S2406 and S3820). Eleven 
patients were identiied as having NPHPT with per-
sistent conirmed results of normal calcium and elevated 
PTH on at least 2 occasions. The prevalence was 0.18% 
(95% CI 0.10-0.31). The mean age of these patients was 
69 years, and 91% were female. None had parathyroid 
surgery.
Two patterns were identiied while studying the nat-
ural history: persistent normocalcemia and intermittent 
hypercalcemia). Intermittent hypercalcemia occurred in 
7 patients (Fig. 2, lower panel). Persistent normocalcemia 
was rare and occurred in only 4 patients (0.06% of the 
whole population) (Fig. 2, upper panel). However, only 
2 of these patients (S0227 and S1620) had consistently 
high PTH, but they were not consistently vitamin D 
Table 1. Different patient categories based on 
calcium metabolism disorders
Categories No. (%)
Normal 5574 (88.76)
HH 172 (2.74)
Hypoparathyroidism 1 (0.02)
Secondary hyperparathyroidism 291 (4.63)
Non-PTH hypercalcemia 6 (0.10)
NPHPT 28 (0.45)
NHYPO 22 (0.35)
Normoparathyroid hypercalcemia 67 (1.07)
Normoparathyroid hypocalcemia 43 (0.68)
Unclassiied abnormal 76 (1.21)
Normal: anyone inside the ellipse; the rest of the groups described were 
outside the ellipse. HH: high adjusted calcium and high PTH. Hypopara-
thyroidism: low adjusted calcium and low PTH. Secondary hyperpara-
thyroidism: a) low adjusted calcium and high PTH or, b) normal adjusted 
calcium and high PTH with 25(OH)D < 50  nmol/L or eGFR < 60  ml/
min/1.73 m2. Non-PTH hypercalcemia: high adjusted calcium and low 
PTH. NPHPT: normal adjusted calcium and high PTH, given that 25(OH)
D ≥ 50  nmol/L and eGFR ≥ 60  ml/min/1.73m2. NHYPO: normal ad-
justed calcium and low PTH. Normoparathyroid hypercalcemia: high 
adjusted calcium and normal PTH. Normoparathyroid hypocalcemia: 
low adjusted calcium and normal PTH. Unclassiied abnormal: normal 
adjusted calcium and normal PTH but outside the ellipse.
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; eGFR, estimated glom-
erular iltration rate; HH, hyperparathyroid hypercalcemia; NHYPO, 
normocalcemic hypoparathyroidism; NPHPT, normocalcemic hyper-
parathyroidism; PTH, parathyroid hormone.
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replete and/or did not have consistently normal eGFR 
(Fig.  3). If the international guidelines were strictly 
applied, the prevalence of NPHPT in this population 
would be zero.
Out of the 172 patients identiied with HH, 29 were 
vitamin D replete and had normal eGFR on the index 
date. The evaluation of their medical records excluded 
one patient because of previous renal transplant (S2706). 
One patient had his or her index date after parathyroid 
surgery and was also excluded (S5826). Eight patients 
were excluded because they had one only result for 
PTH, and the persistence could not be conirmed, and 
one patient was excluded for not having at least 2 con-
sistently high calcium measurements. One patient was 
excluded because FHH could not be ruled out because 
of lack of urine calcium (S2031). The inal PHPT group 
had 17 patients (mean age, 69; 89% female). Twelve pa-
tients had persistent hypercalcemia (70%), whereas the 
remaining 6 had intermittent hypercalcemia, a pattern 
also seen in patients with NPHPT.
The control population group consisted of 300 indi-
viduals (mean age, 67 years; 71% female). There was no 
Table 2. Patients checked for inclusion in normocalcemic hyperparathyroidism group
Study 
No. Age, y Sex Medical Files Check
Persistence 
of Calcium 
and PTH
Natural History of Adjusted 
Calcium
S0189 65 F Excluded—anticonvulsants   
S0227 59 F Included Yes Persistent normocalcemia
S0449 65 F Excluded—treated 
pseudohypoparathyroidism
  
S0567 72 F Excluded—tertiary 
hyperparathyroidism-renal 
transplant
  
S0696 75 F Excluded—bisphosphonates   
S0757 68 F Included Yes Intermittent hypercalcemia
S0871 83 M Excluded—bisphosphonates   
S0911 70 F Included Yes Persistent normocalcemia
S1194 74 F Excluded—bisphosphonates   
S1620 75 F Included Yes Persistent normocalcemia
S1692 79 F Excluded—bisphosphonates   
S1753 86 M Included Yes Intermittent hypercalcemia
S2406 67 F Included No  
S2453 57 F Included Yes Intermittent hypercalcemia
S2654 88 F Excluded—Crohn— 
bisphosphonates—furosemide
  
S2720 83 F Included Yes Intermittent hypercalcemia
S3021 64 F Included Yes Persistent normocalcemia
S3703 72 F Excluded—anticonvulsants   
S3812 70 F Included  Intermittent hypercalcemia
S3820 49 F Included No  
S3841 84 F Excluded—bisphosphonates   
S3882 69 F Excluded—hypercalciuria   
S4392 66 F Included Yes Intermittent hypercalcemia
S4618 59 F Included Yes Intermittent hypercalcemia
S4903 59 M Excluded—renal transplant   
S5321 78 F Excluded—bisphosphonates   
S5369 64 F Excluded—hypercalciuria   
S5408 82 F Excluded—furosemide   
Abbreviations: F, female; M, male; PTH, parathyroid hormone.
Figure 2. The 2 patterns identiied in patients with normocalcemic 
hyperparathyroidism (NPHPT) when studying the natural history of 
adjusted calcium. Top igure, patient S1620, Persistent normocalcemia 
and, bottom igure, patient S2720, intermittent hypercalcemia. 
Arrows represent index day (day of bone mineral density scan). X-axes 
represent year of follow-up. Adj.Ca, adjusted calcium.
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statistically signiicant difference in age or sex distribu-
tion between the groups (all P > .05).
The baseline characteristics on the index date are 
summarized in Table 3. The 3 groups had signiicant dif-
ferences in adjusted calcium on the index date. PTH did 
not differ between the NPHPT and PHPT groups. The 
groups had similar age- and sex-adjusted BMD results. 
Phosphate was signiicantly lower in the PHPT group 
compared to the control group. All the other variables 
studied did not have any differences between the 3 
groups at baseline.
After taking all the follow-up measurements into 
account, the mean adjusted calcium was still found to be 
signiicantly lower in the NPHPT group compared with 
the PHPT group (2.52 and 2.74 mmol/L, respectively). 
The control group had signiicantly lower adjusted cal-
cium levels than all the other groups (2.35 mmol/L, all 
pairwise comparisons P < .001). PTH did not differ 
Figure 3. Means and range of values of different analytes in the 11 normocalcemic hyperparathyroidism (NPHPT) patients. The dashed lines 
represent the reference interval for adjusted calcium, the upper reference interval for parathyroid hormone (PTH), and the desired level for 25(OH)
D and estimated glomerular iltration rate (eGFR). Persistent normocalcemia was rare, only occurred in 4 patients (shown in the graph with arrows). 
However, only 2 patients (S0227 and S1620) had consistently high PTH. These patients were not consistently vitamin D replete and/or did not have 
consistently normal eGFR. PHPT, primary hyperparathyroidism.
doi:10.1210/clinem/dgaa084 https://academic.oup.com/jcem  7
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signiicantly between NPHPT and PHPT (115.4 and 
116.0  ng/L, respectively) but was signiicantly higher 
than in the control group (48.1 ng/L, P < .001) (Fig. 4). 
The PHPT and NPHPT groups had similar calcium 
variability (within-subject SD [95% CI]: 0.088 [0.079, 
0.097] and 0.089 [0.080, 1.000] mmol/L, respect-
ively). The variability of calcium in the control group 
was slightly lower than for PHPT and NPHPT (within-
subject SD 0.083 [0.080, 0.085] mmol/L). The 24-hour 
urine calcium was higher in the PHPT group compared 
to the NPHPT groups (mean, 7.51 and 4.25 mmol/24 h, 
respectively) but the difference was not signiicant 
(P = .063).
Discussion
The international guidelines suggest that patients with 
NPHPT should have consistently normal values of cal-
cium. Moreover, PTH should be high on at least 2 to 
3 consecutive measurements. However, we observed in 
this population that persistent normocalcemia is rarely 
the case and using a single measurement to identify 
NPHPT patients can lead to overestimation of its preva-
lence. Patients with NPHPT usually have intermittent 
hypercalcemia as do PHPT patients, and we believe that 
NPHPT is a variant of PHPT. The intermittent nature of 
serum calcium both in NPHPT and PHPT results from 
Table 3. Characteristics of the 3 groups on index date
Control (n = 300) NPHPT (n = 11) PHPT (n = 17) P
Female (%) 214 (71) 10 (92) 15 (88) .122
Age, ya 70 (20) 68 (11) 67 (6) .975
BMI (g/cm2)c 25.6 (25.0, 26.3) 30.1 (24.4, 34.0) 26.2 (23.4, 28.9) .303
PTH (ng/L)c 42.5 (40.8, 44.2) 106.8 (86.9, 123.9) 102.4 (89.0, 112.4) < .001
Adjusted calcium (mmol/L)b 2.37 (0.08) 2.55 (0.05) 2.75 (0.11) < .001
Phosphate (mmol/L)b 1.12 (0.18) 1.04 (0.14) 0.89 (0.16) < .001
Alkaline phosphatase (IU/L)a 78 (37) 98 (33) 88 (27) .070
25(OH)D (nmol/L)a 78.9 (32.9) 62.8 (23.5) 71.4 (30.5) .083
Z score spineb –0.1 (1.7) 0.2 (2.2) –0.2 (1.3) .932
Z score neckb –0.4 (1.0) –0.1 (1.3) –0.4 (0.8) .770
Results of pairwise comparisons: PTH in the control group differed signiicantly from both the NPHPT and PHPT groups, but there was no statistically 
signiicant difference between the NPHPT and PHPT groups. Adjusted calcium differed signiicantly between all groups. Phosphate differed signii-
cantly only between the PHPT and control group.
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; n, number of patients; NPHPT, normocalcemic hyperparathyroidism; PHPT: pri-
mary hyperparathyroidism; PTH, parathyroid hormone. Values in bold were signiicant.
aShown as median (interquartile range).
bShown as mean (SD).
cShown as geometric mean (95% CI).
Figure 4. Boxplots showing the variability of calcium and parathyroid hormone (PTH) in the normal population and patients with primary 
hyperparathyroidism (PHPT) and normocalcemic hyperparathyroidism (NPHPT). The mean adjusted calcium was found to be signiicantly lower in 
the NPHPT group compared with the PHPT group (P < .001). The normal group had signiicantly lower adjusted calcium levels than all the other 
groups (P < .001). PTH did not differ signiicantly between these groups but was signiicantly higher than the normal population (P < .001).
8  Schini et al  NPHPT: Prevalence and Natural History J Clin Endocrinol Metab, April 2020, 105(4):1–16
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the relatively high variability of serum calcium in all pa-
tient groups.
The studies available for the prevalence of NPHPT 
use different deinitions and patient populations. Often 
the baseline data are the only ones analyzed, without 
evaluation of persistence. To study the natural history, 
only one further measurement during follow-up is used 
and the variability of calcium in the follow-up period is 
not described.
To our knowledge, only 2 studies have reported the 
prevalence of NPHPT from referral centers (Table  4), 
one of them having the highest prevalence in the lit-
erature (8.9%) (15). The mean adjusted calcium was 
similar between the NPHPT group and the rest of the 
patients, a pattern not seen in our study. They also re-
ported higher levels of PTH in the NPHPT group (109.5 
[45.2] vs 39.1 [14.3] pg/mL, P < .001] (15). Another 
estimate of prevalence from a referral center is from a 
group in the Czech Republic. They report 187 patients 
(1.2%) with NPHPT (16). The prevalence of NPHPT 
was also studied in the general population and was re-
ported to be between 0.1% and 6% (Table 4).
The results for the natural history remain contro-
versial with some studies reporting no conversion to 
hypercalcemia (19, 24, 25), whereas others report a 
small percentage of patients becoming hypercalcemic 
(16, 18, 20, 26, 27). The problem with the studies on 
natural history is that, although they might check per-
sistence at baseline on 2 to 3 occasions, they then check 
the laboratory measurements on only 1 occasion after 
a certain period; if at that point the patient has high 
calcium, they conclude that the patient has progressed 
to hypercalcemia. All the studies are summarized in 
Table 5. Silverberg and Bilezikian found hypercalcemia 
in 3 patients after 1 year of follow-up. The researchers 
from this paper irst proposed that NPHPT is the irst 
phase of a biphasic disease course, which can be fol-
lowed by hypercalcemic hyperparathyroidism (27). The 
group from the Czech Republic followed the 187 pa-
tients with NPHPT for 1 to 7 years. Out of them, 151 
patients (81%) remained normocalcemic, and 36 (19%) 
became hypercalcemic; 24 (67%) increased their cal-
cium to high levels within 2 years, 10 (28%) within 2 
to 4 years, and 2 (5%) after more than 4 years. They 
also reported that 23 out of the 36 patients (64%) had 
persistent hypercalcemia, whereas 13 (36%) had inter-
mittent hypercalcemia, a pattern also observed in our 
study. The mean baseline  calcium of patients who re-
mained normocalcemic was signiicantly lower than 
the ones that became hypercalcemic (16). A  more re-
cent study evaluating NPHPT patients going through 
parathyroidectomy reported that 40.8% of these 
patients had episodes of hypercalcemia more than 
1 year before surgery (28).
We believe that NPHPT is a variant of PHPT. This 
issue has been recently addressed by the irst European 
Society of Endocrinology Workshop (PARAT). In its 
consensus statement, it mentioned that the individual 
variation in total calcium is 4 times narrower than the 
population reference interval and the interindividual 
variability. To ensure that a person has normal calcium, 
we need to know his or her individual range of vari-
ability. There is a chance that individuals might have 
an elevated calcium in comparison with their individual 
range, but still be within the normal population refer-
ence interval for calcium. These patients should prob-
ably be characterized as having PHPT and not NPHPT 
and be followed up and treated accordingly. This is of 
course after excluding causes of secondary hyperpara-
thyroidism (30).
None of our patients progressed to persistent 
hypercalcemia; the patterns observed were either per-
sistent normocalcemia or intermittent hypercalcemia. 
The 4 patients with persistent normocalcemia did not 
fulill all the other criteria according to the international 
guidelines. Our hypothesis is supported by the fact that 
the underlying pathology of NPHPT seems to be similar 
to PHPT. A  few studies report that multiglandular 
disease is more common in NPHPT (31-34) but not all 
reach statistical signiicance (35-37). However, patients 
included in these studies probably had secondary hyper-
parathyroidism resulting from vitamin D deiciency 
and CKD (32, 34). Most studies report that the average 
adenoma weight was lower in the NPHPT group com-
pared to the PHPT group of patients (31, 35, 38).
This hypothesis, however, is not fully supported by 
recently published genetic data on NPHPT. Based on 
the hypothesis that NPHPT can be caused by PTH re-
sistance (38), and the fact that the single-nucleotide 
polymorphism rs17251221 (A986S) in the calcium 
sensing receptor has been linked to PTH resistance, 
researchers in Spain recently investigated the effect of 
this single-nucleotide polymorphism in NPHPT pa-
tients. They recruited and prospectively studied 61 
consecutive patients with NPHPT and asymptomatic 
PHPT. These patients had a follow-up of 1  year to 
check for the persistence of their laboratory investiga-
tions on at least 2 occasions. There were 38 patients 
(n = 24 NPHPT and n = 14 PHPT) with the wild-
type genotype A986A and 23 S allele carriers (n = 20 
A986S or n = 3 S986S). Seventeen NPHPT patients 
were S allele carriers. In these patients, the S allele was 
associated with signiicantly higher levels of serum-
intact PTH (P = .024) after adjusting for factors such 
doi:10.1210/clinem/dgaa084 https://academic.oup.com/jcem  9
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Table 4. Studies evaluating prevalence of normocalcemic hyperparathyroidism
Study Population
No. of NPHPT Patients 
(%); Mean Age, y;Sex Deinition of NPHPT Comments/Limitations
Marques et al   
Brazil (referral center) 
(15)
Analyzed records of 
156 postmenopausal women 
referred to hospital to be screened 
for osteoporosis
14 (8.9); 60.6; 100% female At least 2 samples of adjusted Ca and 
PTH. Excluded: 25(OH)D < 30 ng/
mL, GFR < 40 mL/min, medications 
(bisphosphonates, diuretics, 
anticonvulsants, lithium), metabolic bone 
diseases, GI diseases with malabsorption, 
liver disease, incomplete records
Lower cutoff for eGFR
Šiprová et al  
Czech Republic 
(referral center) 
(16)
15 343 referrals to endocrine center. 
PTH measured in 1180 (patients 
with pathological or marginal levels 
of total Ca, ionized Ca, serum 
phosphate, patients with reduced 
BMD, and with possible PHPT 
diagnosis from medical history)
At baseline: 187 (1.2); 61.1; 
81% female; at follow-up: 151
Normal total and ionized Ca and high PTH 
at irst visit. 25(OH)D ≥ 20 ng/ml (patients 
with low vitamin D were treated, and PTH 
had to be elevated after retest at 3 mo). 
Excluded cases with renal insuficiency, Ca 
malabsorption, hypercalciuria, medications 
(PPI, thiazides, lithium)
Not clear if they excluded people 
on bisphosphonates, GFR 
cutoff not given
Berger et al  
Canada  
(community) (17)
Population-based Canadian 
Multicentre Osteoporosis Study: 
prospective cohort of 9423 
community-dwelling women 
and men living within 50 km of 
9 Canadian cities. 566 men and 
1306 women (n = 1875) age ≥ 35 y 
with available PTH
62 (3.31); NA; NA Normal total Ca and high PTH, 25(OH) 
D ≥ 50 nmol/L, eGFR ≥ 60 mL/ 
min/1.73 m2
85% users of antiresorptives 
and diuretics. Not clear if 
they checked persistence or 
other causes of secondary 
hyperparathyroidism
Cusano et al  
US (community) (18)
DHS: population-based cohort 
study. Evaluated 3450 individuals 
age 18 to 65 y with Ca and PTH 
values.2122 patients had follow-up 
data 8 y later
At baseline: 108 (3.1); 41.3; 
38% female; at follow-up: 
13 (0.6%)
Normal albumin-adjusted Ca and high PTH. 
Excluded renal insuficiency (GFR < 60 mL/
min), 25(OH)D ≤ 20 ng/ 
mL, thiazide, or lithium use
Only single laboratory values 
and did not check persistence.
Lack of data regarding medical 
history and parathyroid surgery.
Not clear if they excluded 
patients on bisphosphonates or 
with hypercalciuria
Cusano et al  
US (community) (18)
Osteoporotic Fractures in Men, an 
unselected community-based study 
in age ≥ 65 y. Evaluated 2364 men 
with calcium and PTH values
9 (0.4); 70.0; 0% female Normal albumin-adjusted Ca and high PTH. 
Excluded renal insuficiency (GFR < 60 mL/
min), 25(OH)D ≤ 20 ng/ 
mL, thiazide use
Same as DHS
García-Martín et al  
Spain (community) 
(19)
Prospective study of 100 healthy 
postmenopausal women. All had 
follow-up 6 y later
6 (6); 56.3; 100% female;  
at follow-up: 6
Normal adjusted Ca and high PTH. 25(OH)
D > 30 ng/mL, normal renal function 
(creatinine clearance > 70 mL/ 
min/1.73 m2)
Not clear if they excluded patients 
on medications. Not clear what 
they deined as “healthy.”
Kontogeorgos et al  
Sweden (community) 
(20)
Random population sample of 
2400 men and women age 25 
to 64 years from World Health 
Organization MONItoring of 
trends and determinants for 
CArdiovascular disease project. 
Investigation in 1995, data on 608, 
including all women age 45 to 64 y, 
every fourth woman age 25 to 44 
y, and every fourth man in all age 
groups (25-64 y), n = 410.
12 (2.0%); 53.3; NA;  
at follow-up: 1 (0.2%)
Normal total Ca and high PTH, 
25(OH) ≥ 50 nmol/L, normal renal function
Patients on bisphosphonates 
and diuretics. Only one blood 
measurement at baseline
1
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Study Population
No. of NPHPT Patients 
(%); Mean Age, y;Sex Deinition of NPHPT Comments/Limitations
Lundgren et al  
Sweden (community) 
(21)
Population-based mammography 
screening in 5202 women age 55 
to 75 years
28 (0.5); no data on age; 100% 
female
Normal ionized Ca. Creatinine < 160 ˩mol/L 
and either a) serum Ca < 2.50 mmol/L + 
PTH > 55 ng/L or b) serum Ca 2.50 to 
2.60 mmol/L + PTH ≥ 35 ng/L. Checked 
for persistence (≥ 3 occasions). Excluded 
malabsorption and family history of 
hypercalcemia
Did not exclude patients on 
medications known to cause 
secondary hyperparathyroidism. 
No vitamin D check
Palermo et al  
Five European 
cities in UK, 
France, Germany 
(community) (11)
Recruited 2419 women (age 55-79 y) 
and 258 women (age 30-40 y) for 
Osteoporosis and Ultrasound Study. 
Follow-up after 6 y in 1416 patients
1 (0.1); no information on age; 
100% female; at follow-up: 
none
Mahalanobis distance used: NPHPT anyone 
outside ellipse with normal adjusted Ca, 
high PTH, 25(OH) 
D ≥ 50 nmol/L, GFR ≥ 60 mL/min
Unclear if they excluded patients 
with other causes of secondary 
hyperparathyroidism (diseases, 
medication)
Rosário et al  
Brazil (community) 
(22)
Prospectively recruited adults ≥ 18 y 
to undergo thyroidectomy for 
nodular disease. Excluded patients 
who had ultrasound because of 
PHPT, patients with a history of 
nephrolithiasis, nephrocalcinosis, 
and pathological fracture, personal 
or family history of multiple 
endocrine neoplasia, or diagnosis 
of medullary thyroid cancer. 
N = 676
Criterion 1:  
46 (6.8%). Only 8.7% had 
altered parathyroid glands 
(adenoma) during gland 
exploration (0.6% of cohort)  
Criterion 2: 30 (4.4%). 
Conirmed pathology: 13.3% 
Criterion 3: 12 (1.8%). 
Conirmed pathology: 33.3% 
Criterion 4: 5 (0.74%). 
Conirmed pathology: 80%
Criterion 1: Normal adjusted and ionized 
Ca and high PTH, conirmed at 2 
measurements, 25(OH)D ≥ 20 ng/ 
dL, eGFR ≥ 40 mLl/min/1.73 m2. 
Excluded: those on diuretics, lithium, 
bisphosphonates, denosumab, 
recombinant PTH, corticosteroids; patients 
with primary aldosteronism, suspicion 
or known diagnosis of malabsorption, 
hyperphosphatemia, Ca/urinary creatine 
ratio ≥ 0.25, or thyroid dysfunction. 
Screened for celiac disease and excluded 
patients with positive antibodies  
Criterion 2: same as criterion 1 but 25(OH)
D ≥ 20 ng/dL, eGFR ≥ 60 mL/ 
min/1.73 m2  
Criterion 3: same as criterion 1 but 25(OH)
D ≥ 30 ng/dL, eGFR ≥ 40 mL/ 
min/1.73 m2  
Criterion 4: same as criterion 1 but 25(OH)
D ≥ 30 ng/dL, eGFR ≥ 60 mL/ 
min/1.73 m2
 
Vignali et al  
Italy (community) 
(23)
Residents of village in Southern Italy 
in 2010 (685 with full data)
3 (0.4); 47; 0% female Normal adjusted Ca and high PTH, 25(OD)
D ≥ 30 ng/mL, eGFR ≥ 60 mL/ 
min/1.73 m2. Excluded people on 
bisphosphonates and thiazides, overt GI 
and metabolic bone diseases
Did not check persistence and 
could not check urine Ca
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; BMD, bone mineral density; Ca, calcium; DHS, Dallas Heart Study; eGFR, estimated glomerular iltration rate; GI, gastrointestinal; NA, not available; NPHPT, 
normocalcemic hyperparathyroidism; PHPT: primary hyperparathyroidism; PPI, proton pump inhibitor; PTH, parathyroid hormone.
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Table 5. Studies evaluating natural history of normocalcemic hyperparathyroidism
Study
Study Population;  
Duration of  
Follow-up Deinition of NPHPT Progression to Hypercalcemia
Ayturk et al (24) 20; 18 mo  
(6-mo intervals)
Normal Ca and high PTH conirmed in at least 3 measurements. 
Excluded chronic renal or liver failure, vitamin D deiciency, 
secondary hyperparathyroidism, treatment with lithium. No 
treatments with thiazide and loop diuretics, phenytoin, lithium, 
glucocorticoids, or oral contraceptives during study
None progressed to hypercalcemia
Tordjman et al (25) 20; 4.1 ± 3.2 y Normal total Ca and high PTH secondary hyperparathyroidism 
excluded (impaired renal function). Three patients had low vitamin 
D levels but correction did not alter PTH levels and did not unmask 
hypercalcemia. Six patients had > 300 mg/24 h urine Ca and 
were given thiazides without affecting PTH levels. Persistence not 
checked at baseline
None of the patients developed 
hypercalcemia. Mean serum calcium levels 
did not change signiicantly (baseline vs 
last)
Garcia-Martin et al (19) 6; 1 y Normal adjusted Ca and high PTH. 25(OH)D > 30 ng/mL, normal 
renal function (creatinine clearance > 70 mL/min/1.73 m2). 
Persistence not checked at baseline
All patients remained normocalcemic
Cusano et al (18) 64; 8 y Normal albumin-adjusted Ca and high PTH. Excluded renal 
insuficiency (GFR < 60 mL/min), 25(OH)D ≤ 20 ng/mL, thiazide or 
lithium use. Persistence not checked at baseline
Hypercalcemia: 1 (1.6%). Persistent normal 
Ca, high PTH: 13 (20%)
Diri et al (26) 16; 4 y Normal total Ca and high PTH, 25(OH)D > 20 ng/mL, repeated Ca 
and PTH measurements 3× with 2-wk intervals, no history of renal 
or liver diseases, no prescriptions known to affect Ca level
One (6.25%) developed hypercalcemia
Kontogeorgos et al (20) 12; 13 y. First assessment 
1995, second 2008 to 
2009, participation rate 
67%
Normal total Ca and high PTH, 25(OH) ≥ 50 nmol/L, normal renal 
function
One (8.33%) developed hypercalcemia. 
Persistent normal Ca, high PTH: 1 (8.33%). 
Two had vitamin D deiciency, normal Ca, 
and high PTH
Silverberg et al (27) 22; up to 1 y Normal adjusted calcium and high PTH. Conirmed on at least 2 
occasions, 8 patients had normal ionized Ca, 25(OH) 
D > 20 ng/mL. Excluded FHH, liver disease, renal disease, urinary 
calcium > 87.5mmol/24h, GI disease with malabsorption, 
metabolic bone disease, medications (lithium, thiazide, oestrogens, 
loop diuretics, bisphosphonates, anticonvulsants)
Three (14%) developed hypercalcemia
Siprova et al (16) 187; 1 to 7 y Normal total and ionized Ca and high PTH. 25(OH)D ≥ 20 ng/ 
ml (patients with low vitamin D were treated, and PTH had to 
be elevated after retested at 3 mo). Excluded cases with renal 
insuficiency, calcium malabsorption, hypercalciuria, medications 
(PPI, thiazides, lithium)
151 (81%) remained normocalcemic for 
whole follow-up period. 36 (19%) became 
hypercalcemic
Lowe et al (29) 37; 3.1 ± 0.3 y Normal adjusted Ca and high PTH, 25(OH)D ≥ 50 nmol/L  
Excluded cases with renal insuficiency (GFR < 40 mL/min/1.73 m2), 
liver disease; signiicant hypercalciuria > 350 mg/24 h, thiazide 
diuretic or lithium use, other metabolic bone diseases (eg, Paget 
disease)
Seven (19%) became hypercalcemic. Patients 
who became hypercalcemic had higher Ca 
levels, higher urinary calcium excretion, 
and were older
Abbreviations: 25(OH)D, 25-hydroxyvitamin D; Ca, calcium; eGFR, estimated glomerular iltration rate; FHH, familial hypocalciuric hypercalcemia; NA, not available; NPHPT, normocalcemic hyperparathyr-
oidism; PHPT: primary hyperparathyroidism; PPI, proton pump inhibitor; PTH, parathyroid hormone.
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as vitamin D and calcium concentrations. There was 
no association with the S allele in PHPT patients (39).
In our series, we found a similar variability of ad-
justed calcium in patients with NPHPT and PHPT. The 
variability of calcium and PTH has been studied previ-
ously in a prospective series of surgically proven PHPT. 
In this study (6), the deinition of NPHPT was every 
measurement of calcium being less than 10.2  mg/dL 
(2.55 mmol/L), and only 1.1% of the patients fulilled 
this criterion. Almost all the patients with PHPT had 
variable calcium levels, with 74% having intermittent 
hypercalcemia within the previous year. This study did 
not include a control group but mentioned that serum 
calcium was more variable in PHPT patients com-
pared to the same patients before developing this dis-
order. The variability before was described to be 0.19 
(0.09) mg/dL (0.0475 [0.0225] mmol/L). After conver-
sion to PHPT, the variability more than doubled (0.1 
[0.0825] mmol/L), with calcium varying by more than 
1 mg/dL (0.25 mmol/L) from month to month in some 
cases. The authors suggested this could be a loss of cal-
cium homeostasis by a parathyroid tumor. Patients with 
NPHPT were reported as an exception, presenting with 
minimal variability, like the one in the patients before 
PHPT. Minimal variability is not the inding from our 
study, because NPHPT and PHPT patients both had 
similar calcium variability (6).
The variability described in calcium in these pa-
tients complicates their monitoring. According to the 
international guidelines, calcium and PTH should be 
tested every year, whereas a BMD check should be 
performed every 1 to 2  years. If there is a progres-
sion to hypercalcemia, patients should be treated ac-
cording to the guidelines on asymptomatic PHPT (40). 
However, a majority of these patients have intermittent 
hypercalcemia; the subsequent results might be con-
fusing both for the care provider and the patient as to 
whether surgery would be recommended.
We used a statistical approach to deine the different 
categories in this population. Our results showed that 
a large percentage of participants were considered 
“normal” (inside the ellipse) using this approach, even 
though they had elevated PTH according to the refer-
ence interval. The individuals who were normal but had 
higher PTH than the reference interval were found to 
be signiicantly older than those who were normal and 
also had normal PTH according to the current reference 
interval (data not shown). These results align well with 
the fact that PTH is known to increase with age. This in-
crease was recently found to be independent of 25(OH)
D, ionized calcium, phosphate, and renal function 
(41). It has been previously suggested that age-related 
PTH reference intervals should be established (2). Our 
study supports this statement. By using the current ref-
erence interval in everyday practice, we are probably 
overdiagnosing NPHPT and may be subjecting older 
individuals to unnecessary testing. An increase of the 
upper limit of the reference interval in PTH could alter 
the number of patients diagnosed with this disorder.
This study describes the largest population ever 
studied to identify NPHPT and provides data during a 
long follow-up period (5 years). There are several limi-
tations to this study, however. The samples were not 
fasting, blood was taken with a tourniquet, and ionized 
calcium was not available. The methods for vitamin D 
and eGFR changed during the follow-up period and 
that might have affected some results. We have used a 
25(OH)D threshold of 50 nmol/L for identifying high 
PTH due to D deiciency, but the cross-sectional data 
indicate that values between 50 and 75 nmol/L might be 
associated with slight elevations of PTH, thus resulting 
in overdiagnosis of NPHPT. Many researchers recom-
mend using a higher cutoff of 75 nmol/L. We have used 
the cutoff advised by the Royal Osteoporosis Society 
guidelines and the Fourth International Workshop on 
Asymptomatic Primary Hyperparathyroidism (2, 13). 
The impact of implementing the CKD-EPI equation 
is that it may have improved the accuracy in patients 
with an eGFR of 50 to 60 mL/min/1.73 m2 and might 
have resulted in fewer people being clustered as CKD. 
However, it might have increased the number of older 
people having CKD. The equation used to calculate the 
pooled SD cannot really distinguish between variations 
due to the progression of the disease or those due to 
natural variation. We assume that when taking meas-
urements close to each other, the pooled SD would es-
timate the method variation and the variability of the 
assay. Because the measurements in this population are 
further away, we believe that the variability is due to 
the within-subject variability. Moreover, none of our pa-
tients had progressive disease as seen in the natural his-
tory graphs, so we believe that this is all due to natural 
variation. This was a retrospective observational study 
and the number of measurements varied from patient to 
patient. The interval between the measurements was not 
the same, as expected in a real-life setting. This limited 
the possibility of further analyses. The analysis for the 
within-subject SD did not take into account the effect 
of time. Ideally, to give a more accurate estimate of the 
variance, a prospective observational study should be 
designed having the same number of measurements for 
each patient at regular intervals. The analysis should 
preferably be conducted using a model that takes time 
into account. Despite the limitations, this study provided 
doi:10.1210/clinem/dgaa084 https://academic.oup.com/jcem  13
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a guide to how adjusted calcium varies between the dif-
ferent groups described.
The patients studied were identiied from a re-
ferral center and were evaluated for causes of sec-
ondary osteoporosis so they might be different from 
the general population. On the other hand, NPHPT is 
usually diagnosed during the evaluation of secondary 
osteoporosis and thus, mainly found in referral cen-
ters. Studying a referral population has the advantage 
of evaluating how common NPHPT is in a referral 
population with osteoporosis and whether screening 
for NPHPT is useful.
Another group that is mentioned in this cohort, is the 
normoparathyroid hypercalcemia one. These patients 
were previously been described to progress to PHPT 
(42). It was not within the scope of this study to evaluate 
these patients further, but it is among our future plans.
The question resulting from this study is whether 
NPHPT exists and, if it does, whether the current def-
inition used is the most appropriate. We believe there 
are 3 ways forward. If we adjust the reference interval 
for PTH for age and use the current deinition, NPHPT 
may not exist, as shown in this study. Another ap-
proach would be to revisit the current deinition, and 
NPHPT should be deined as having the average cal-
cium within normal limits (and not requiring it to be 
persistently normal). Using the same approach, PHPT 
should be considered as having a high average calcium. 
In this case, 10 out of our 11 included patients would 
be classiied as NPHPT, and 16 out of 17 PHPT patients 
would be classiied as having PHPT (Fig. 5).
Another way forward would be to consider NPHPT 
as a variant of PHPT and follow-up and treat according 
to the current guidelines as suggested in the consensus 
statement of the irst PARAT. This is supported by many 
studies in the literature showing similar characteristics 
from these 2 groups of patients. It is also supported by 
the fact that the underlying pathology of NPHPT seems 
to be similar to PHPT. We believe, based on the results 
from this study, that this is the best approach to follow 
in clinical practice.
In conclusion, persistent normocalcemia in patients 
with NPHPT is rare. If the international guidelines were 
strictly applied, the prevalence of NPHPT in this popula-
tion would be zero. Our study is the irst that studies the 
natural history of patients with NPHPT in so much de-
tail and provides data from a long follow-up period. We 
suggest that the deinition be revisited and NPHPT be de-
ined as having the average calcium within normal limits 
and not persistently normal, at least in a research set-
ting. Subsequent hypercalcemia in these patients should 
be treated with caution, and any decisions for surgery 
should be made after persistently high levels of calcium 
have been conirmed. Another approach is to accept that 
NPHPT is a mild form of PHPT. Our recommendation 
for managing a patient with high PTH and normal cal-
cium is continuous observation for the development of 
persistent hypercalcemic hyperparathyroidism.
Figure 5. Means and range of values for adjusted calcium in the 11 normocalcemic hyperparathyroidism (NPHPT) patients and the 17 primary 
hyperparathyroidism (PHPT) patients. The dashed lines represent the reference interval. This igure shows that if the mean calcium was used to 
deine the different groups, all but one patient in the left graph would be classiied as NPHPT and all but one patient in the right graph would be 
classiied as PHPT.
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